MerLion’s finafloxacin might be the answer to painful UTIs

1
1169

Source: http://www.merlionpharma.com/?q=node/227 MerLion Pharmaceuticals, a biopharmaceutical company based in Singapore and Berlin, has said that they have achieved positive results from a phase 2 trial with finafloxacin, a drug for treating patients hospitalized with complicated urinary tract infections (cUTI), including a high proportion with pyelonephritis.

Finafloxacin is a fluoroquinolone antibiotic that demonstrates a substantially improved therapeutic profile over the existing gold standard and greater utility in treating many severe infections, including those caused by a number of resistant gram-negative pathogens. Most other antibiotics, including other fluoroquinolones, have decreased activity in acidic conditions. However, Finafloxacin claims to surpass these acidic barriers.

The results from the phase 2 study indicate that patients treated with a five day course of finafloxacin had a higher, more rapid and more sustained level of bacterial eradication and improved clinical outcomes than those treated with the current standard of care (ciprofloxacin taken twice daily for 10 days). The trial’s primary and secondary endpoints were all successfully achieved. Finafloxacin was found to be both safe and tolerable, with only a small number of class-typical adverse events observed.

MerLion has developed IV and oral formulations of finafloxacin with equivalent bioavailability, offering physicians the choice of initially treating infections in hospital or at out-patient infusion centres for one to three days with the IV regimen, then allowing patients to complete their treatment at home; reducing the risk of complications and/or secondary infections. Hence, MerLion’s finafloxacin might help you say goodbye to painful UTIs.

Source:

This article is based on materials provided by: http://www.merlionpharma.com/?q=node/227

Disclaimer: This article does not reflect any personal views of the authors/editors

Previous articleTemperature stress leads to coral bleaching
Next articleMali is now Ebola-free
Scientist-entrepreneur-manager-journalist: -Co-founder, Author; Former Assistant Editor and Director, Biotechin.Asia, Biotech Media Pte. Ltd.; -Founder & CEO, SciGlo (www.sciglo.com); -Programme Management Officer, SBIC, A*STAR (former Research Fellow). --Sandhya graduated from University of Madras, India (B.Sc Microbiology and M.Sc Biotechnology) and received her Ph.D from the Nanyang Technological University, Singapore. She worked on oxidative stress in skin, skeletal, adipose tissue and cardiac muscle for a decade from 2006-2016. She is currently working as a Programme Management Officer handling projects and grants at Singapore Bioimaging Consortium (SBIC), Agency for Science, Technology and Research (A*STAR). Earlier to this she was a Research Fellow in the Fat Metabolism and Stem Cell Group at SBIC. Sandhya was also the Vice President and Publicity Chair of A*PECSS (A*STAR Post Doc Society) (2014-2016). Recently she founded a platform for scientists - SciGlo (www.sciglo.com) and is a startup mentor at Vertical VC (Finland). She is an ardent lover of science and enjoys globe trotting and good vegetarian food.